TCF4 and neoplasm: A study from Yoshito's group demonstrated that a novel drug, C‐122, inhibits tumour growth in hepatocellular carcinoma through down‐regulation of TCF4 and downstream genes such as SPP1, AXIN2, MMP7, ASPH, CD24, ANXA1 and CAMK2N1.56